11beta-aryl Estradiol Imaging Agents for Breast Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current molecular imaging agents for estrogen receptors, such as 16α-fluoroestradiol, face limitations in receptor binding affinity, metabolic stability, and tissue distribution, leading to suboptimal imaging of estrogen receptor-positive breast cancer, with high background signal and limited clinical utility.
Innovation Solution
Development of 11β-aryl estradiol-based molecular imaging agents with high specific activity and receptor binding affinity, utilizing a convergent modular synthesis approach and 'click' chemistry to attach imaging moieties, enhancing target tissue uptake and reducing non-specific binding and metabolism.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If 16α-fluoroestradiol is used as an imaging agent, then estrogen receptor binding is achieved, but metabolic stability is poor and background signal is high
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of estradiol at the 11β position with various aryl groups (phenyl, naphthyl, biphenyl) and substituents. These structural parameter changes enhance metabolic stability by preventing enzymatic degradation while maintaining receptor binding affinity through preservation of key pharmacophoric elements.
Solution Approach 2:
The patent creates composite molecular structures by combining the estradiol core with aryl substituents at the 11β position. These composite structures integrate the receptor-binding capabilities of estradiol with the metabolic stability of aromatic groups, achieving both high affinity and resistance to metabolism.
2Measurement precision
If conventional imaging agents are used, then imaging capability is provided, but tissue distribution is suboptimal with high background signal
Solution Approach 1:
The patent applies local quality by introducing specific aryl substituents at the 11β position of estradiol, which locally modifies the molecule's interaction with biological systems. This local modification enhances target tissue uptake through improved pharmacokinetic properties while reducing non-specific binding and background signal in normal tissues.
Solution Approach 2:
By changing the chemical parameters of the imaging agent through 11β-aryl substitution, the patent optimizes tissue distribution characteristics. The modified agents demonstrate improved hydrophobicity and membrane permeability, leading to enhanced tumor uptake and reduced background signal for better imaging contrast.
3Ease of manufacture
If modular synthesis approach is used, then manufacturing flexibility is improved, but synthesis complexity increases
Solution Approach 1:
The patent employs segmentation in synthesis by dividing the molecular construction into modular components: the estradiol core, the 11β-aryl substituent, and various functional groups. This modular approach allows independent optimization of each component and facilitates systematic exploration of structure-activity relationships while maintaining synthetic tractability.
Data Source
AI summary
Compounds useful for molecular imaging of cells expressing estrogen receptors are provided. Also provided are intermediates for making the compounds and methods of making the compounds using a modular convergent strategy. Further, methods of making the intermediates are described, as well as methods of diagnosing disease in a subject by using the compounds as imaging agents.